nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.14	0.293	CbGbCtD
Methylnaltrexone—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.129	0.271	CbGbCtD
Methylnaltrexone—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.106	0.222	CbGbCtD
Methylnaltrexone—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.102	0.213	CbGbCtD
Methylnaltrexone—Flatulence—Miglitol—type 2 diabetes mellitus	0.00536	0.0137	CcSEcCtD
Methylnaltrexone—Erythema—Tolbutamide—type 2 diabetes mellitus	0.00489	0.0125	CcSEcCtD
Methylnaltrexone—Erythema—Tolazamide—type 2 diabetes mellitus	0.00445	0.0114	CcSEcCtD
Methylnaltrexone—Stinging—Losartan—type 2 diabetes mellitus	0.00428	0.0109	CcSEcCtD
Methylnaltrexone—Erythema—Acarbose—type 2 diabetes mellitus	0.00427	0.0109	CcSEcCtD
Methylnaltrexone—Flatulence—Acarbose—type 2 diabetes mellitus	0.00421	0.0108	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Miglitol—type 2 diabetes mellitus	0.00383	0.00979	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Linagliptin—type 2 diabetes mellitus	0.00372	0.00951	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Miglitol—type 2 diabetes mellitus	0.00363	0.00928	CcSEcCtD
Methylnaltrexone—Erythema—Repaglinide—type 2 diabetes mellitus	0.00357	0.00912	CcSEcCtD
Methylnaltrexone—Abdominal pain—Miglitol—type 2 diabetes mellitus	0.00351	0.00897	CcSEcCtD
Methylnaltrexone—Skin disorder—Linagliptin—type 2 diabetes mellitus	0.00349	0.00892	CcSEcCtD
Methylnaltrexone—Oedema—Acarbose—type 2 diabetes mellitus	0.00349	0.00892	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Tolbutamide—type 2 diabetes mellitus	0.00344	0.00881	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Nateglinide—type 2 diabetes mellitus	0.00325	0.00831	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Chlorpropamide—type 2 diabetes mellitus	0.00313	0.00801	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Tolazamide—type 2 diabetes mellitus	0.00313	0.00801	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Linagliptin—type 2 diabetes mellitus	0.0031	0.00793	CcSEcCtD
Methylnaltrexone—Diarrhoea—Miglitol—type 2 diabetes mellitus	0.00304	0.00776	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Repaglinide—type 2 diabetes mellitus	0.00301	0.00771	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Acarbose—type 2 diabetes mellitus	0.00301	0.0077	CcSEcCtD
Methylnaltrexone—Erythema—Glipizide—type 2 diabetes mellitus	0.00295	0.00754	CcSEcCtD
Methylnaltrexone—Oedema—Repaglinide—type 2 diabetes mellitus	0.00291	0.00744	CcSEcCtD
Methylnaltrexone—Flatulence—Glipizide—type 2 diabetes mellitus	0.00291	0.00743	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Nateglinide—type 2 diabetes mellitus	0.0029	0.00742	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Acarbose—type 2 diabetes mellitus	0.00285	0.00729	CcSEcCtD
Methylnaltrexone—Skin disorder—Repaglinide—type 2 diabetes mellitus	0.00283	0.00723	CcSEcCtD
Methylnaltrexone—Flatulence—Pioglitazone—type 2 diabetes mellitus	0.00278	0.00712	CcSEcCtD
Methylnaltrexone—Abdominal pain—Acarbose—type 2 diabetes mellitus	0.00276	0.00705	CcSEcCtD
Methylnaltrexone—Erythema—Glimepiride—type 2 diabetes mellitus	0.00275	0.00704	CcSEcCtD
Methylnaltrexone—Oedema—Rosiglitazone—type 2 diabetes mellitus	0.00275	0.00703	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Nateglinide—type 2 diabetes mellitus	0.00275	0.00703	CcSEcCtD
Methylnaltrexone—Flatulence—Sitagliptin—type 2 diabetes mellitus	0.0027	0.00691	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Rosiglitazone—type 2 diabetes mellitus	0.0027	0.0069	CcSEcCtD
Methylnaltrexone—Abdominal pain—Nateglinide—type 2 diabetes mellitus	0.00266	0.0068	CcSEcCtD
Methylnaltrexone—Nausea—Miglitol—type 2 diabetes mellitus	0.00264	0.00674	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Repaglinide—type 2 diabetes mellitus	0.00251	0.00642	CcSEcCtD
Methylnaltrexone—Diarrhoea—Chlorpropamide—type 2 diabetes mellitus	0.00248	0.00635	CcSEcCtD
Methylnaltrexone—Diarrhoea—Linagliptin—type 2 diabetes mellitus	0.00246	0.00628	CcSEcCtD
Methylnaltrexone—Oedema—Glipizide—type 2 diabetes mellitus	0.00241	0.00616	CcSEcCtD
Methylnaltrexone—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.0024	0.00614	CcSEcCtD
Methylnaltrexone—Dizziness—Tolazamide—type 2 diabetes mellitus	0.0024	0.00614	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Pioglitazone—type 2 diabetes mellitus	0.00239	0.00611	CcSEcCtD
Methylnaltrexone—Diarrhoea—Acarbose—type 2 diabetes mellitus	0.00239	0.0061	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Repaglinide—type 2 diabetes mellitus	0.00238	0.00608	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Rosiglitazone—type 2 diabetes mellitus	0.00237	0.00607	CcSEcCtD
Methylnaltrexone—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00237	0.00606	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Glipizide—type 2 diabetes mellitus	0.00233	0.00595	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Sitagliptin—type 2 diabetes mellitus	0.00232	0.00593	CcSEcCtD
Methylnaltrexone—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.00231	0.0059	CcSEcCtD
Methylnaltrexone—Oedema—Pioglitazone—type 2 diabetes mellitus	0.00231	0.0059	CcSEcCtD
Methylnaltrexone—Abdominal pain—Repaglinide—type 2 diabetes mellitus	0.0023	0.00588	CcSEcCtD
Methylnaltrexone—Diarrhoea—Nateglinide—type 2 diabetes mellitus	0.0023	0.00588	CcSEcCtD
Methylnaltrexone—Erythema—Glyburide—type 2 diabetes mellitus	0.00227	0.00581	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Pioglitazone—type 2 diabetes mellitus	0.00226	0.00578	CcSEcCtD
Methylnaltrexone—Skin disorder—Pioglitazone—type 2 diabetes mellitus	0.00224	0.00573	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Pioglitazone—type 2 diabetes mellitus	0.00223	0.0057	CcSEcCtD
Methylnaltrexone—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00222	0.00569	CcSEcCtD
Methylnaltrexone—Vomiting—Acarbose—type 2 diabetes mellitus	0.00222	0.00567	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Sitagliptin—type 2 diabetes mellitus	0.0022	0.00562	CcSEcCtD
Methylnaltrexone—Skin disorder—Sitagliptin—type 2 diabetes mellitus	0.00218	0.00556	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Glimepiride—type 2 diabetes mellitus	0.00217	0.00555	CcSEcCtD
Methylnaltrexone—Nausea—Tolazamide—type 2 diabetes mellitus	0.00216	0.00551	CcSEcCtD
Methylnaltrexone—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00216	0.00551	CcSEcCtD
Methylnaltrexone—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00214	0.00547	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Bromocriptine—type 2 diabetes mellitus	0.0021	0.00537	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Glipizide—type 2 diabetes mellitus	0.00208	0.00532	CcSEcCtD
Methylnaltrexone—Nausea—Acarbose—type 2 diabetes mellitus	0.00207	0.0053	CcSEcCtD
Methylnaltrexone—Pain—Glipizide—type 2 diabetes mellitus	0.00206	0.00526	CcSEcCtD
Methylnaltrexone—Erythema—Gliclazide—type 2 diabetes mellitus	0.00204	0.00521	CcSEcCtD
Methylnaltrexone—Oedema—Bromocriptine—type 2 diabetes mellitus	0.00203	0.00518	CcSEcCtD
Methylnaltrexone—Flatulence—Gliclazide—type 2 diabetes mellitus	0.00201	0.00514	CcSEcCtD
Methylnaltrexone—Nausea—Nateglinide—type 2 diabetes mellitus	0.002	0.00511	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Pioglitazone—type 2 diabetes mellitus	0.00199	0.00509	CcSEcCtD
Methylnaltrexone—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.00199	0.00509	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.00199	0.00508	CcSEcCtD
Methylnaltrexone—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.00197	0.00503	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Glipizide—type 2 diabetes mellitus	0.00197	0.00503	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.00194	0.00496	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.00193	0.00494	CcSEcCtD
Methylnaltrexone—Pain—Sitagliptin—type 2 diabetes mellitus	0.00192	0.0049	CcSEcCtD
Methylnaltrexone—Abdominal pain—Glipizide—type 2 diabetes mellitus	0.0019	0.00487	CcSEcCtD
Methylnaltrexone—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.00188	0.00481	CcSEcCtD
Methylnaltrexone—Oedema—Glyburide—type 2 diabetes mellitus	0.00185	0.00474	CcSEcCtD
Methylnaltrexone—Vomiting—Repaglinide—type 2 diabetes mellitus	0.00185	0.00473	CcSEcCtD
Methylnaltrexone—Flatulence—Valsartan—type 2 diabetes mellitus	0.00185	0.00472	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Glimepiride—type 2 diabetes mellitus	0.00184	0.0047	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Sitagliptin—type 2 diabetes mellitus	0.00183	0.00468	CcSEcCtD
Methylnaltrexone—Flatulence—Orlistat—type 2 diabetes mellitus	0.00182	0.00466	CcSEcCtD
Methylnaltrexone—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00182	0.00465	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.00182	0.00465	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.00179	0.00458	CcSEcCtD
Methylnaltrexone—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.00178	0.00454	CcSEcCtD
Methylnaltrexone—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.00177	0.00453	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.00175	0.00447	CcSEcCtD
Methylnaltrexone—Nausea—Repaglinide—type 2 diabetes mellitus	0.00173	0.00442	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.00172	0.00441	CcSEcCtD
Methylnaltrexone—Erythema—Metformin—type 2 diabetes mellitus	0.00171	0.00436	CcSEcCtD
Methylnaltrexone—Flatulence—Metformin—type 2 diabetes mellitus	0.00168	0.0043	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Bromocriptine—type 2 diabetes mellitus	0.00166	0.00424	CcSEcCtD
Methylnaltrexone—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.00165	0.00421	CcSEcCtD
Methylnaltrexone—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00163	0.00418	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.00163	0.00417	CcSEcCtD
Methylnaltrexone—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00162	0.00413	CcSEcCtD
Methylnaltrexone—Erythema—Irbesartan—type 2 diabetes mellitus	0.00161	0.00412	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.00161	0.00411	CcSEcCtD
Methylnaltrexone—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.0016	0.0041	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.0016	0.00409	CcSEcCtD
Methylnaltrexone—Dizziness—Glipizide—type 2 diabetes mellitus	0.00159	0.00407	CcSEcCtD
Methylnaltrexone—Flatulence—Irbesartan—type 2 diabetes mellitus	0.00159	0.00406	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.00158	0.00405	CcSEcCtD
Methylnaltrexone—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.00158	0.00404	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.00156	0.004	CcSEcCtD
Methylnaltrexone—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.00154	0.00393	CcSEcCtD
Methylnaltrexone—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.00153	0.00392	CcSEcCtD
Methylnaltrexone—Vomiting—Glipizide—type 2 diabetes mellitus	0.00153	0.00391	CcSEcCtD
Methylnaltrexone—Oedema—Valsartan—type 2 diabetes mellitus	0.00153	0.00391	CcSEcCtD
Methylnaltrexone—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00153	0.0039	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.00152	0.00387	CcSEcCtD
Methylnaltrexone—Erythema—Losartan—type 2 diabetes mellitus	0.00151	0.00387	CcSEcCtD
Methylnaltrexone—Oedema—Orlistat—type 2 diabetes mellitus	0.00151	0.00386	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.0015	0.00383	CcSEcCtD
Methylnaltrexone—Flatulence—Losartan—type 2 diabetes mellitus	0.00149	0.00382	CcSEcCtD
Methylnaltrexone—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00149	0.0038	CcSEcCtD
Methylnaltrexone—Skin disorder—Valsartan—type 2 diabetes mellitus	0.00148	0.0038	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.00148	0.00379	CcSEcCtD
Methylnaltrexone—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00148	0.00379	CcSEcCtD
Methylnaltrexone—Skin disorder—Orlistat—type 2 diabetes mellitus	0.00147	0.00375	CcSEcCtD
Methylnaltrexone—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.00146	0.00375	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.00146	0.00373	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.00144	0.00369	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00144	0.00367	CcSEcCtD
Methylnaltrexone—Nausea—Glipizide—type 2 diabetes mellitus	0.00143	0.00366	CcSEcCtD
Methylnaltrexone—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00143	0.00365	CcSEcCtD
Methylnaltrexone—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00142	0.00364	CcSEcCtD
Methylnaltrexone—Pain—Gliclazide—type 2 diabetes mellitus	0.00142	0.00364	CcSEcCtD
Methylnaltrexone—Oedema—Metformin—type 2 diabetes mellitus	0.00139	0.00356	CcSEcCtD
Methylnaltrexone—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.00139	0.00355	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.00137	0.00349	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.00136	0.00348	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.00136	0.00348	CcSEcCtD
Methylnaltrexone—Skin disorder—Metformin—type 2 diabetes mellitus	0.00135	0.00346	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.00135	0.00344	CcSEcCtD
Methylnaltrexone—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00134	0.00343	CcSEcCtD
Methylnaltrexone—Nausea—Glimepiride—type 2 diabetes mellitus	0.00133	0.00341	CcSEcCtD
Methylnaltrexone—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00133	0.0034	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.00132	0.00337	CcSEcCtD
Methylnaltrexone—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.00132	0.00336	CcSEcCtD
Methylnaltrexone—Oedema—Irbesartan—type 2 diabetes mellitus	0.00131	0.00336	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.0013	0.00333	CcSEcCtD
Methylnaltrexone—Erythema—Ramipril—type 2 diabetes mellitus	0.0013	0.00332	CcSEcCtD
Methylnaltrexone—Pain—Orlistat—type 2 diabetes mellitus	0.00129	0.0033	CcSEcCtD
Methylnaltrexone—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.00129	0.0033	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.00129	0.00329	CcSEcCtD
Methylnaltrexone—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.00128	0.00326	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.00127	0.00325	CcSEcCtD
Methylnaltrexone—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.00127	0.00324	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00125	0.0032	CcSEcCtD
Methylnaltrexone—Oedema—Losartan—type 2 diabetes mellitus	0.00124	0.00316	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.00124	0.00316	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.00121	0.0031	CcSEcCtD
Methylnaltrexone—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.00121	0.00309	CcSEcCtD
Methylnaltrexone—Nausea—Bromocriptine—type 2 diabetes mellitus	0.0012	0.00308	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.0012	0.00307	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.0012	0.00306	CcSEcCtD
Methylnaltrexone—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.00119	0.00305	CcSEcCtD
Methylnaltrexone—Vomiting—Glyburide—type 2 diabetes mellitus	0.00118	0.00301	CcSEcCtD
Methylnaltrexone—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.00114	0.00291	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.00114	0.00291	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.00113	0.0029	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP1A2—type 2 diabetes mellitus	0.00113	0.168	CrCbGaD
Methylnaltrexone—Pain—Irbesartan—type 2 diabetes mellitus	0.00112	0.00287	CcSEcCtD
Methylnaltrexone—Nausea—Glyburide—type 2 diabetes mellitus	0.0011	0.00281	CcSEcCtD
Methylnaltrexone—Abdominal pain—Metformin—type 2 diabetes mellitus	0.0011	0.00281	CcSEcCtD
Methylnaltrexone—Dizziness—Gliclazide—type 2 diabetes mellitus	0.0011	0.00281	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.0011	0.00281	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	0.00107	0.00275	CcSEcCtD
Methylnaltrexone—Oedema—Ramipril—type 2 diabetes mellitus	0.00106	0.00271	CcSEcCtD
Methylnaltrexone—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00106	0.00271	CcSEcCtD
Methylnaltrexone—Pain—Losartan—type 2 diabetes mellitus	0.00106	0.0027	CcSEcCtD
Methylnaltrexone—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00105	0.00267	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.00104	0.00266	CcSEcCtD
Methylnaltrexone—Abdominal pain—Irbesartan—type 2 diabetes mellitus	0.00104	0.00266	CcSEcCtD
Methylnaltrexone—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.00103	0.00264	CcSEcCtD
Methylnaltrexone—Skin disorder—Ramipril—type 2 diabetes mellitus	0.00103	0.00263	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.00102	0.00262	CcSEcCtD
Methylnaltrexone—Oxymorphone—CYP3A4—type 2 diabetes mellitus	0.00101	0.151	CrCbGaD
Methylnaltrexone—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	0.00101	0.00259	CcSEcCtD
Methylnaltrexone—Dizziness—Valsartan—type 2 diabetes mellitus	0.00101	0.00258	CcSEcCtD
Methylnaltrexone—Dizziness—Orlistat—type 2 diabetes mellitus	0.000999	0.00255	CcSEcCtD
Methylnaltrexone—Nausea—Gliclazide—type 2 diabetes mellitus	0.000988	0.00253	CcSEcCtD
Methylnaltrexone—Abdominal pain—Losartan—type 2 diabetes mellitus	0.000977	0.0025	CcSEcCtD
Methylnaltrexone—Vomiting—Valsartan—type 2 diabetes mellitus	0.000972	0.00249	CcSEcCtD
Methylnaltrexone—Vomiting—Orlistat—type 2 diabetes mellitus	0.00096	0.00246	CcSEcCtD
Methylnaltrexone—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000952	0.00244	CcSEcCtD
Methylnaltrexone—Dizziness—Metformin—type 2 diabetes mellitus	0.000921	0.00235	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000915	0.00234	CcSEcCtD
Methylnaltrexone—Nausea—Valsartan—type 2 diabetes mellitus	0.000908	0.00232	CcSEcCtD
Methylnaltrexone—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000899	0.0023	CcSEcCtD
Methylnaltrexone—Nausea—Orlistat—type 2 diabetes mellitus	0.000897	0.00229	CcSEcCtD
Methylnaltrexone—Hydrocodone—CYP3A4—type 2 diabetes mellitus	0.000886	0.132	CrCbGaD
Methylnaltrexone—Vomiting—Metformin—type 2 diabetes mellitus	0.000885	0.00226	CcSEcCtD
Methylnaltrexone—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000869	0.00222	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	0.000867	0.00222	CcSEcCtD
Methylnaltrexone—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000846	0.00216	CcSEcCtD
Methylnaltrexone—Abdominal pain—Ramipril—type 2 diabetes mellitus	0.000838	0.00214	CcSEcCtD
Methylnaltrexone—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000835	0.00214	CcSEcCtD
Methylnaltrexone—Nausea—Metformin—type 2 diabetes mellitus	0.000827	0.00211	CcSEcCtD
Methylnaltrexone—Dizziness—Losartan—type 2 diabetes mellitus	0.000818	0.00209	CcSEcCtD
Methylnaltrexone—Oxycodone—CYP3A4—type 2 diabetes mellitus	0.000809	0.121	CrCbGaD
Methylnaltrexone—Vomiting—Losartan—type 2 diabetes mellitus	0.000786	0.00201	CcSEcCtD
Methylnaltrexone—Nausea—Irbesartan—type 2 diabetes mellitus	0.00078	0.002	CcSEcCtD
Methylnaltrexone—Buprenorphine—CYP3A4—type 2 diabetes mellitus	0.000745	0.111	CrCbGaD
Methylnaltrexone—Naloxone—CYP3A4—type 2 diabetes mellitus	0.00074	0.11	CrCbGaD
Methylnaltrexone—Hydromorphone—CYP3A4—type 2 diabetes mellitus	0.000734	0.11	CrCbGaD
Methylnaltrexone—Nausea—Losartan—type 2 diabetes mellitus	0.000734	0.00188	CcSEcCtD
Methylnaltrexone—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000725	0.00185	CcSEcCtD
Methylnaltrexone—Dizziness—Ramipril—type 2 diabetes mellitus	0.000701	0.00179	CcSEcCtD
Methylnaltrexone—Vomiting—Ramipril—type 2 diabetes mellitus	0.000674	0.00172	CcSEcCtD
Methylnaltrexone—Naloxone—ALB—type 2 diabetes mellitus	0.000645	0.0963	CrCbGaD
Methylnaltrexone—Nausea—Ramipril—type 2 diabetes mellitus	0.00063	0.00161	CcSEcCtD
Methylnaltrexone—OPRK1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	8.2e-05	0.000655	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AVP—type 2 diabetes mellitus	8.15e-05	0.000652	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CDO1—type 2 diabetes mellitus	8.03e-05	0.000642	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPD2—type 2 diabetes mellitus	8.03e-05	0.000642	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—C3—type 2 diabetes mellitus	8.01e-05	0.000641	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	7.91e-05	0.000632	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	7.82e-05	0.000625	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IAPP—type 2 diabetes mellitus	7.77e-05	0.000622	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	7.75e-05	0.00062	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INSR—type 2 diabetes mellitus	7.72e-05	0.000618	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	7.68e-05	0.000614	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AK1—type 2 diabetes mellitus	7.66e-05	0.000612	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	7.61e-05	0.000609	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	7.61e-05	0.000609	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SPRY2—type 2 diabetes mellitus	7.61e-05	0.000609	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	7.59e-05	0.000607	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	7.58e-05	0.000606	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	7.54e-05	0.000603	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—GNB3—type 2 diabetes mellitus	7.5e-05	0.0006	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	7.44e-05	0.000595	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RBP4—type 2 diabetes mellitus	7.41e-05	0.000593	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GLP1R—type 2 diabetes mellitus	7.41e-05	0.000593	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AVP—type 2 diabetes mellitus	7.4e-05	0.000592	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—MMP3—type 2 diabetes mellitus	7.4e-05	0.000592	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	7.36e-05	0.000589	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCKAR—type 2 diabetes mellitus	7.29e-05	0.000583	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—C3—type 2 diabetes mellitus	7.27e-05	0.000582	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	7.22e-05	0.000578	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC5A4—type 2 diabetes mellitus	7.07e-05	0.000565	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MAT1A—type 2 diabetes mellitus	7.07e-05	0.000565	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EDN1—type 2 diabetes mellitus	7.04e-05	0.000563	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	7.03e-05	0.000562	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	7.01e-05	0.000561	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	7.01e-05	0.000561	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	6.93e-05	0.000554	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AGT—type 2 diabetes mellitus	6.91e-05	0.000553	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—G6PC—type 2 diabetes mellitus	6.82e-05	0.000546	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HBA2—type 2 diabetes mellitus	6.82e-05	0.000546	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ND1—type 2 diabetes mellitus	6.82e-05	0.000546	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ENPP1—type 2 diabetes mellitus	6.82e-05	0.000546	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPP1R3C—type 2 diabetes mellitus	6.82e-05	0.000546	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	6.82e-05	0.000546	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	6.79e-05	0.000543	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CYBA—type 2 diabetes mellitus	6.79e-05	0.000543	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—C3—type 2 diabetes mellitus	6.77e-05	0.000541	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	6.68e-05	0.000535	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	6.68e-05	0.000534	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GHRL—type 2 diabetes mellitus	6.65e-05	0.000532	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PLAT—type 2 diabetes mellitus	6.65e-05	0.000532	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCGR—type 2 diabetes mellitus	6.61e-05	0.000529	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	6.61e-05	0.000529	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IAPP—type 2 diabetes mellitus	6.57e-05	0.000525	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CALCA—type 2 diabetes mellitus	6.57e-05	0.000525	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INSR—type 2 diabetes mellitus	6.53e-05	0.000522	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	6.43e-05	0.000514	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	6.41e-05	0.000513	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	6.41e-05	0.000512	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	6.38e-05	0.000511	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	6.38e-05	0.00051	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	6.29e-05	0.000503	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—OXCT1—type 2 diabetes mellitus	6.24e-05	0.000499	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYTB—type 2 diabetes mellitus	6.24e-05	0.000499	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	6.19e-05	0.000495	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	6.16e-05	0.000492	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—C3—type 2 diabetes mellitus	6.15e-05	0.000492	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	6.11e-05	0.000488	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SRD5A1—type 2 diabetes mellitus	6.08e-05	0.000487	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GCG—type 2 diabetes mellitus	6.08e-05	0.000486	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	6.08e-05	0.000486	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.98e-05	0.000478	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.96e-05	0.000477	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	5.94e-05	0.000475	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	5.93e-05	0.000474	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	5.93e-05	0.000474	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AGT—type 2 diabetes mellitus	5.84e-05	0.000467	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD17B3—type 2 diabetes mellitus	5.8e-05	0.000464	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ACACA—type 2 diabetes mellitus	5.8e-05	0.000464	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—STAR—type 2 diabetes mellitus	5.8e-05	0.000464	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	5.77e-05	0.000461	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	5.74e-05	0.000459	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CYBA—type 2 diabetes mellitus	5.74e-05	0.000459	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	5.69e-05	0.000455	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	5.64e-05	0.000451	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GHRL—type 2 diabetes mellitus	5.62e-05	0.000449	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PLAT—type 2 diabetes mellitus	5.62e-05	0.000449	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	5.59e-05	0.000447	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	5.59e-05	0.000447	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ABCC8—type 2 diabetes mellitus	5.56e-05	0.000445	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CBS—type 2 diabetes mellitus	5.56e-05	0.000445	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	5.55e-05	0.000444	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	5.4e-05	0.000432	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—COX2—type 2 diabetes mellitus	5.36e-05	0.000428	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC5A2—type 2 diabetes mellitus	5.36e-05	0.000428	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.29e-05	0.000423	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NCOA6—type 2 diabetes mellitus	5.26e-05	0.000421	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.24e-05	0.000419	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	5.23e-05	0.000418	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	5.2e-05	0.000416	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UCP2—type 2 diabetes mellitus	5.17e-05	0.000414	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD11B1—type 2 diabetes mellitus	5.17e-05	0.000414	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—UCP3—type 2 diabetes mellitus	5.17e-05	0.000414	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AVP—type 2 diabetes mellitus	5.17e-05	0.000414	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.17e-05	0.000414	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.15e-05	0.000412	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	5.14e-05	0.000411	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	5.14e-05	0.000411	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.13e-05	0.00041	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.07e-05	0.000406	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	5.06e-05	0.000404	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	5.04e-05	0.000403	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOB—type 2 diabetes mellitus	5e-05	0.0004	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.98e-05	0.000398	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.92e-05	0.000393	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PCK1—type 2 diabetes mellitus	4.86e-05	0.000389	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	4.81e-05	0.000385	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LPL—type 2 diabetes mellitus	4.77e-05	0.000382	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	4.72e-05	0.000378	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	4.72e-05	0.000378	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.67e-05	0.000374	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HK1—type 2 diabetes mellitus	4.55e-05	0.000364	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.48e-05	0.000358	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	4.47e-05	0.000358	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	4.43e-05	0.000354	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HSD3B2—type 2 diabetes mellitus	4.4e-05	0.000352	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPA—type 2 diabetes mellitus	4.4e-05	0.000352	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCKR—type 2 diabetes mellitus	4.4e-05	0.000352	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—KCNJ11—type 2 diabetes mellitus	4.4e-05	0.000352	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.4e-05	0.000352	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	4.37e-05	0.000349	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	4.37e-05	0.000349	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	4.35e-05	0.000348	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	4.33e-05	0.000346	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—C3—type 2 diabetes mellitus	4.3e-05	0.000344	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	4.29e-05	0.000343	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	4.22e-05	0.000338	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALDOB—type 2 diabetes mellitus	4.22e-05	0.000337	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	4.21e-05	0.000336	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	4.16e-05	0.000332	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.1e-05	0.000328	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.09e-05	0.000327	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.08e-05	0.000326	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	4.03e-05	0.000323	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.01e-05	0.000321	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—LEP—type 2 diabetes mellitus	4e-05	0.00032	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOE—type 2 diabetes mellitus	4e-05	0.00032	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.95e-05	0.000316	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	3.95e-05	0.000316	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	3.92e-05	0.000314	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	3.78e-05	0.000303	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.77e-05	0.000302	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	3.72e-05	0.000297	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	3.66e-05	0.000293	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—C3—type 2 diabetes mellitus	3.63e-05	0.00029	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	3.59e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	3.59e-05	0.000287	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.57e-05	0.000285	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	3.52e-05	0.000281	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	3.49e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	3.49e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	3.49e-05	0.000279	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	3.47e-05	0.000278	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	3.46e-05	0.000277	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	3.45e-05	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	3.45e-05	0.000276	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—INS—type 2 diabetes mellitus	3.42e-05	0.000273	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	3.41e-05	0.000273	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	3.39e-05	0.000271	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	3.38e-05	0.00027	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	3.38e-05	0.00027	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	3.37e-05	0.00027	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.36e-05	0.000269	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	3.34e-05	0.000267	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.3e-05	0.000264	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.3e-05	0.000264	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.29e-05	0.000263	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.19e-05	0.000255	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.14e-05	0.000251	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	3.13e-05	0.000251	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	3.13e-05	0.000251	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	3.13e-05	0.000251	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	3.08e-05	0.000246	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	3.05e-05	0.000244	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.02e-05	0.000241	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3e-05	0.00024	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3e-05	0.00024	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	2.98e-05	0.000239	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—INS—type 2 diabetes mellitus	2.89e-05	0.000231	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	2.87e-05	0.000229	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	2.84e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	2.83e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	2.83e-05	0.000227	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.82e-05	0.000226	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	2.79e-05	0.000223	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	2.79e-05	0.000223	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	2.78e-05	0.000222	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	2.76e-05	0.000221	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	2.72e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	2.72e-05	0.000217	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	2.65e-05	0.000212	CbGpPWpGaD
Methylnaltrexone—OPRK1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.57e-05	0.000205	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.54e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	2.53e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	2.53e-05	0.000203	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.53e-05	0.000202	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.4e-05	0.000192	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	2.38e-05	0.000191	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.38e-05	0.00019	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.34e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	2.34e-05	0.000187	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.33e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	2.33e-05	0.000186	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	2.3e-05	0.000184	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	2.23e-05	0.000179	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.22e-05	0.000177	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	2.17e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	2.17e-05	0.000174	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.16e-05	0.000173	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.15e-05	0.000172	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.14e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	2.13e-05	0.000171	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	2.09e-05	0.000167	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	2.08e-05	0.000166	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.03e-05	0.000163	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	2.03e-05	0.000162	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.01e-05	0.000161	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	2e-05	0.00016	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.98e-05	0.000158	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	1.97e-05	0.000158	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.94e-05	0.000155	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	1.92e-05	0.000154	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	1.88e-05	0.000151	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	1.87e-05	0.00015	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.82e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	1.82e-05	0.000146	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	1.79e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	1.79e-05	0.000143	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	1.77e-05	0.000141	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	1.67e-05	0.000134	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	1.64e-05	0.000131	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	1.56e-05	0.000125	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	1.53e-05	0.000122	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.49e-05	0.000119	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	1.4e-05	0.000112	CbGpPWpGaD
Methylnaltrexone—OPRK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.38e-05	0.00011	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	1.34e-05	0.000107	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	1.34e-05	0.000107	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.26e-05	0.000101	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	1.22e-05	9.79e-05	CbGpPWpGaD
Methylnaltrexone—OPRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.16e-05	9.31e-05	CbGpPWpGaD
Methylnaltrexone—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	6.15e-06	4.92e-05	CbGpPWpGaD
